Abstract
The recent successful clinical translation of nuclear theranostics ([1][1],[2][2]) fueled industry investment in the radiopharmaceutical market ([3][3]). Among other examples, Novartis invested $6 billion to acquire Endocyte (177Lu-PSMA-617) and Advanced Accelerator Applications (AAA; 177Lu-DOTATATE
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
